Topical Roflumilast Rewrites the Safety Story by Route
Topical roflumilast shows how route of administration can rewrite a PDE4 inhibitor's safety profile, concentrating action in skin rather than circulation.
Topic
Pde4 Inhibitor
Topic
Pde4 Inhibitor
Roflumilast Eases Sexual Difficulties in Genital Psoriasis
Roflumilast improved sexual difficulties in psoriasis patients with genital involvement, adding to the topical PDE4 inhibitor's p…
Difamilast Approved as Topical PDE4 Inhibitor for Atopic Dermatitis
Difamilast joins crisaborole (Eucrisa) as the second topical PDE4 inhibitor cleared for U.S. atopic dermatitis, per Pharmacy Time…
Roflumilast 0.05% Cream Shows Early AD Clearance in Infants
Roflumilast cream 0.05% shows early atopic dermatitis clearance in infants, per Contemporary Pediatrics — a steroid-free PDE4 sig…
Roflumilast 0.05% Cream Clears Atopic Dermatitis Early in Infants
A Contemporary Pediatrics report signals early atopic dermatitis clearance in infants treated with once-daily roflumilast cream 0…